Frazier Life Sciences IX, L.P. 3
3 · Tarsus Pharmaceuticals, Inc. · Filed Oct 15, 2020
Insider Transaction Report
Form 3
Frazier Life Sciences IX, L.P.
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (1,390,376 underlying)Series C Preferred Stock
→ Common Stock (214,281 underlying)
Footnotes (3)
- [F1]The Series B Preferred Stock shall automatically convert into shares of Common Stock, on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date.
- [F2]The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein
- [F3]The Series C Preferred Stock shall automatically convert into shares of Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series C Preferred Stock has no expiration date.